TapewireFind a company

person · Reporting owner

CALLICUTT JACK W

Disclosed activity across 1 company

Tapewire entity
69095
SEC CIK
0001266773

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GALECTIN THERAPEUTICS INCGALT · Entity 5577Chief Financial OfficerJanuary 16, 2026January 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GALECTIN THERAPEUTICS INC

Report date January 16, 2026 · Filed January 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2036-01-16Direct65,000 Reported balance After 2026-01-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-16 · Grant · Acquired 65,000 · Balance 65,000

F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect100,000 Reported balance After 2026-01-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-01-16 · Grant · Acquired 100,000 · Balance 100,000

F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F4: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F3: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

F3: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

F4: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 16, 2026 Filed Jan 21, 2026 21:47 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 GrantRestricted Stock Unit · Derivative 100,000 $0.00 $0.00
Disclosure

SEC source: 0001133416-26-000030 · form4.xml · derivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires not disclosed

F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

Read SEC document
January 16, 2026 Filed Jan 21, 2026 21:47 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 GrantStock option (right to buy) · Derivative 65,000 $0.00 Strike: $3.04 $0.00
Disclosure

SEC source: 0001133416-26-000030 · form4.xml · derivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2036-01-16

F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

Read SEC document
January 06, 2026 Filed Jan 6, 2026 21:54 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon Stock 20,354 $3.67 $74,695.11
Disclosure

SEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 4

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F6 · price: The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 21:54 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon Stock 25,732 $3.90 $100,298.19
Disclosure

SEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 3

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,968

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:54 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon Stock 13,914 $4.20 $58,394.28
Disclosure

SEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,700

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:54 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon Stock 60,000 $0.00 $0.00
Disclosure

SEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

Read SEC document
January 01, 2026 Filed Jan 6, 2026 21:54 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionRestricted Stock Unit · Derivative 60,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001133416-26-000006 · form4.xml · derivative · entry 5

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

F4 · shares: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F4 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

F4 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock (right to buy) · Derivative 18,190 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · derivative · entry 15

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 18,190 shares

Expires 2034-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 28,120 $0.00 Strike: $1.98 $0.00
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · derivative · entry 14

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 28,120 shares

Expires 2032-12-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 18,210 $6.22 $113,320.83
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 10

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.30. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 18,210 $1.11 $20,213.10
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 9

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 28,100 $6.22 $174,866.30
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 8

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.30. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 18, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 28,100 $1.98 $55,638.00
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 7

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,714

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 2,323 $0.00 Strike: $1.23 $0.00
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · derivative · entry 13

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,750

Underlying: Common stock · 2,323 shares

Expires 2035-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F4 · derivative.exercise_date: The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 19,701 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · derivative · entry 12

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,190

Underlying: Common stock · 19,701 shares

Expires 2034-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 9,586 $0.00 Strike: $1.98 $0.00
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · derivative · entry 11

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,120

Underlying: Common stock · 9,586 shares

Expires 2032-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 2,323 $6.03 $14,011.64
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 6

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 2,323 $1.23 $2,857.29
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 5

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,937

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 19,701 $6.03 $118,830.52
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 4

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 19,701 $1.11 $21,868.11
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 3

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,315

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 9,586 $6.03 $57,819.88
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 9,586 $1.98 $18,980.28
Disclosure

SEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 1,736 $0.00 Strike: $1.23 $0.00
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · derivative · entry 9

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,073

Underlying: Common stock · 1,736 shares

Expires 2035-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F4 · derivative.exercise_date: The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 1,675 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · derivative · entry 8

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,891

Underlying: Common stock · 1,675 shares

Expires 2034-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 1,880 $0.00 Strike: $1.98 $0.00
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · derivative · entry 7

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,706

Underlying: Common stock · 1,880 shares

Expires 2032-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 1,736 $6.03 $10,467.73
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 6

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 1,736 $1.23 $2,135.28
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 5

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 1,675 $6.03 $10,094.56
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 4

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 1,675 $1.11 $1,859.25
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 3

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 1,880 $6.02 $11,321.36
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 10, 2025 Filed Nov 12, 2025 21:01 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 1,880 $1.98 $3,722.40
Disclosure

SEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,694

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 200 $0.00 Strike: $1.72 $0.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · derivative · entry 9

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,809

Underlying: Common stock · 200 shares

Expires 2034-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F4 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 200 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · derivative · entry 8

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,566

Underlying: Common stock · 200 shares

Expires 2034-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 200 $0.00 Strike: $1.98 $0.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · derivative · entry 7

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,586

Underlying: Common stock · 200 shares

Expires 2032-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 200 $6.00 $1,200.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 6

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 200 $1.72 $344.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 5

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,814

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 200 $6.00 $1,200.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 4

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 200 $1.11 $222.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 3

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,814

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 200 $6.00 $1,200.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 21:07 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 200 $1.98 $396.00
Disclosure

SEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,814

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 10,741 $0.00 Strike: $1.72 $0.00
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · derivative · entry 18

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,009

Underlying: Common stock · 10,741 shares

Expires 2034-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 8,974 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · derivative · entry 17

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,766

Underlying: Common stock · 8,974 shares

Expires 2034-01-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F4 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 8,914 $0.00 Strike: $1.98 $0.00
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · derivative · entry 16

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,786

Underlying: Common stock · 8,914 shares

Expires 2032-01-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 10,741 $6.07 $65,197.87
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 12

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 10,741 $1.72 $18,474.52
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 11

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,355

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 8,974 $6.07 $54,472.18
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 10

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 8,974 $1.11 $9,961.14
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 9

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,588

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 SaleCommon stock 8,914 $6.07 $54,107.98
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 8

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Read SEC document
November 04, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionCommon stock 8,914 $1.98 $17,649.72
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 7

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,528

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

Read SEC document
November 03, 2025 Filed Nov 5, 2025 21:06 UTC GALECTIN THERAPEUTICS INC GALT · Entity 5577 Exercise / conversionStock option (right to buy) · Derivative 1,250 $0.00 Strike: $1.72 $0.00
Disclosure

SEC source: 0001133416-25-000043 · form4.xml · derivative · entry 15

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,750

Underlying: Comm stock · 1,250 shares

Expires 2034-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

F5 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.